glp-1 sglt2 SGLTi and in HF Real-World Evidence for GLP-1 Receptor

Missing doses or inconsistent timing can result in suboptimal glucose control and reduced therapeutic benefit

Patients switching between semaglutide and tirzepatide should understand the conversion protocols involved

The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) demonstrated cardiovascular risk reduction over multi-year follow-up periods (approximately 3.8 years and 2.1 years, respectively)

Understanding the three-entity structure helps you know who to contact with clinical questions (your provider, via the platform), billing questions (FeelGood support), and medication concerns (FeelGood support, who coordinates with the pharmacy)